MAIA MAIA Biotechnology
- 3.720
- -0.200-5.10%
- 3.738
- +0.018+0.49%
MAIA Biotechnology News
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of GameStop Corp. (NYSE:GME) fell sharply during Friday's session after the company released worse-than-expected first-quarter results before schedule and filed to sell up to 75 million shares.
MAIA Biotechnology Announces Validation Of Clinical And Regulatory Pathways For Telomere-Targeting Cancer Therapies Following FDA Approval Of Geron's Imetelstat
MAIA Biotechnology Announces Validation Of Clinical And Regulatory Pathways For Telomere-Targeting Cancer Therapies Following FDA Approval Of Geron's Imetelstat
Express News | Maia Biotechnology's Telomere Targeting Functionality Is Shown Viable by Fda’s Approval of a Telomerase Inhibitor Agent Therapy
Express News | Maia Biotechnology Inc- Engaged in Research and Development for a Portfolio of Second-Generation Thio-Like Compounds.
Express News | Maia Biotechnology Inc - Maia's Phase 2 Thio-101 Clinical Trial Is Expected to Near Completion in 2024
Express News | Maia Biotechnology-Thio Works Well in All Doses &Has Excellent Safety Profile,but 180Mg Shown Greatest Efficacy &Well Tolerated Vs Existing Therapies
Express News | Maia Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersENDRA Life Sciences (NASDAQ:NDRA) stock increased by 79.2% to $0.15 during Wednesday's regular session. The company's market cap stands at $1.6 million. Rezolute (NASDAQ:RZLT) stock moved upwar
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersConcord Medical Services (NYSE:CCM) shares moved upwards by 131.0% to $4.85 during Tuesday's after-market session. The company's market cap stands at $210.6 million. Calidi Biotherapeutics (AME
Express News | Maia Biotechnology Inc - Anticipate Full Efficacy Data From Thio-101 in Second Half of This Year
Express News | Maia Biotechnology Inc - to Date, Treatment With Thio + Cemiplimab Has Been Generally Well Tolerated in a Heavily Pre-Treated Patient Population
Express News | Maia Biotechnology Reveals New Clinical Data Showing Thio's Strong Efficacy in Non-Small Cell Lung Cancer
MAIA Biotechnology Reveals New Clinical Data Showing THIO's Strong Efficacy in Non-Small Cell Lung Cancer
THIO's favorable disease control and overall response rates exceed reported standard-of-care data in third line treatment MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage
MAIA Biotechnology TO Present At BIO International Convention 2024
MAIA Biotechnology TO Present At BIO International Convention 2024
MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
Poster to present new efficacy data from Phase 2 THIO-101 trial in non-small cell lung cancer (NSCLC) MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company
MAIA Biotechnology | 10-Q: Quarterly report
MAIA Biotechnology Unveils New Business Overview Presentation
MAIA Biotechnology Shares Hit 52-Week High After Director Stock Purchase
By Chris Wack MAIA Biotechnology shares hit their 52-week high Monday after it said that independent director Stan Smith made an individual purchase of 147,000 shares, and warrants for 147,000 shares
NYSE American New 52-Week Highs And Lows
New Highs 7 COMPANY SYMBOL HIGH VOLUME ------- ------ ---- ------ Air Industries Group AIRI 7.24 71,596 Ar
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement
Dr. Smith has participated in every MAIA funding round CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company de
Analysis
Price Target
No Data
